Literature DB >> 12667032

Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.

Sandeep Vijan1, Rodney A Hayward.   

Abstract

BACKGROUND: Hypertension in patients with type 2 diabetes mellitus is a prevalent condition that leads to substantial morbidity and mortality.
PURPOSE: To evaluate the goals and optimal agents for treatment of hypertension in type 2 diabetes. DATA SOURCES: Review of the medical literature STUDY SELECTION: Randomized trials that evaluated the pharmacologic treatment of hypertension in patients with diabetes and reported microvascular and macrovascular outcomes. DATA EXTRACTION: Studies were identified by using the Cochrane Library, MEDLINE, meta-analyses, review articles, and expert recommendation. The searches of the Cochrane Library and MEDLINE were performed in May 2000 and updated in April 2002. Data were abstracted to standardized forms by a single reviewer and were confirmed by a second reviewer. DATA SYNTHESIS: Treatment of hypertension in type 2 diabetes provides dramatic benefit. Target diastolic blood pressures of less than 80 mm Hg appear optimal; systolic targets have not been as rigorously evaluated, but targets of 135 mm Hg or less are reasonable. Studies that compare drug classes do not suggest obviously superior agents. However, it is reasonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps angiotensin-converting enzyme (ACE) inhibitors may be the preferred first-line agents for treatment of hypertension in diabetes. beta-Blockers and calcium-channel blockers are more effective than placebo, but they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhibitors; however, study results are inconsistent in this regard.
CONCLUSIONS: Treatment of hypertension in type 2 diabetes, with blood pressure goals of 135/80 mm Hg, provides dramatic benefits. Thiazide diuretics, angiotensin II receptor blockers, and ACE inhibitors may be the best first-line treatments, although other agents are usually necessary and goals may not be achieved even with three or four agents. Aggressive blood pressure control may be the most important factor in preventing adverse outcomes in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667032     DOI: 10.7326/0003-4819-138-7-200304010-00018

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  62 in total

1.  Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing?

Authors:  Eve A Kerr; Michelle A Lucatorto; Rob Holleman; Mary M Hogan; Mandi L Klamerus; Timothy P Hofer
Journal:  Arch Intern Med       Date:  2012-06-25

2.  Health Care Disparities and Diabetes Care: Practical Considerations for Primary Care Providers.

Authors:  Richard O White; Bettina M Beech; Stephania Miller
Journal:  Clin Diabetes       Date:  2009-06

3.  Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data.

Authors:  Theodore Mazzone
Journal:  Circulation       Date:  2010-11-23       Impact factor: 29.690

Review 4.  Diabetes: treating hypertension.

Authors:  Sandeep Vijan
Journal:  BMJ Clin Evid       Date:  2009-11-09

5.  The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers.

Authors:  Elbert S Huang; Qi Zhang; Sydney E S Brown; Melinda L Drum; David O Meltzer; Marshall H Chin
Journal:  Health Serv Res       Date:  2007-12       Impact factor: 3.402

Review 6.  Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials.

Authors:  Aanand D Naik; Tim T Issac; Richard L Street; Mark E Kunik
Journal:  J Am Board Fam Med       Date:  2007 Sep-Oct       Impact factor: 2.657

7.  Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.

Authors:  Alex Z Fu; Ying Qiu; Larry Radican; Donald D Yin; Panagiotis Mavros
Journal:  Cardiovasc Diabetol       Date:  2010-04-21       Impact factor: 9.951

8.  Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes.

Authors:  Kazuo Eguchi; Thomas G Pickering; Satoshi Hoshide; Joji Ishikawa; Shizukiyo Ishikawa; Joseph E Schwartz; Kazuyuki Shimada; Kazuomi Kario
Journal:  Am J Hypertens       Date:  2008-02-21       Impact factor: 2.689

Review 9.  Diabetes: treating hypertension.

Authors:  Sandeep Vijan
Journal:  BMJ Clin Evid       Date:  2014-06-26

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.